Literature DB >> 25006133

Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.

Masaru Imamura1, David Shook2, Takahiro Kamiya1, Noriko Shimasaki1, Sally M H Chai1, Elaine Coustan-Smith1, Chihaya Imai3, Dario Campana1.   

Abstract

Natural killer (NK) cell survival and, hence, cytotoxicity requires cytokine support. We determined whether expression of interleukin-15 (IL-15) in a nonsecretory, membrane-bound form could sustain NK cell growth. We linked the human IL15 gene to that encoding CD8α transmembrane domain (mbIL15). After retroviral transduction, human NK cells expressed mbIL15 on the cell surface; IL-15 secretion was negligible. Survival of mbIL15-NK cells without interleukin-2 (IL-2) after 7-day culture was vastly superior to that of mock-transduced NK cells (P < .001, n = 15) and of NK cells expressing nonmembrane-bound IL-15 (P = .025, n = 9); viable mbIL15-NK cells were detectable for up to 2 months. In immunodeficient mice, mbIL15-NK cells expanded without IL-2 and were detectable in all tissues examined (except brain) in much higher numbers than mock-transduced NK cells (P < .001). Expansion further increased with IL-2. The primary mechanism of mbIL15 stimulation was autocrine; it activated IL-15 signaling and antiapoptotic signaling. NK cells expressing mbIL15 had higher cytotoxicity against leukemia, lymphoma, and solid tumor cells in vitro and against leukemia and sarcoma cells in xenograft models. Thus, mbIL15 confers independent growth to NK cells and enhances their antitumor capacity. Infusion of mbIL15-NK cells would allow NK cell therapy without the potential adverse effects of cytokine administration.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25006133     DOI: 10.1182/blood-2014-02-556837

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  The future of medical education.

Authors:  Khay-Guan Yeoh
Journal:  Singapore Med J       Date:  2019-01       Impact factor: 1.858

2.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Authors:  Lenka V Hurton; Harjeet Singh; Amer M Najjar; Kirsten C Switzer; Tiejuan Mi; Sourindra Maiti; Simon Olivares; Brian Rabinovich; Helen Huls; Marie-Andrée Forget; Vrushali Datar; Partow Kebriaei; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

3.  Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.

Authors:  Meisam Naeimi Kararoudi; Brian P Tullius; Nitin Chakravarti; Emily J Pomeroy; Branden S Moriarity; Kathie Beland; Aurelien B L Colamartino; Elie Haddad; Yaya Chu; Mitchell S Cairo; Dean A Lee
Journal:  Semin Hematol       Date:  2020-11-19       Impact factor: 3.851

4.  Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.

Authors:  Takahiro Kamiya; See Voon Seow; Desmond Wong; Murray Robinson; Dario Campana
Journal:  J Clin Invest       Date:  2019-03-12       Impact factor: 14.808

5.  IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Authors:  Yumeng Mao; Vincent van Hoef; Xiaonan Zhang; Erik Wennerberg; Julie Lorent; Kristina Witt; Laia Masvidal; Shuo Liang; Shannon Murray; Ola Larsson; Rolf Kiessling; Andreas Lundqvist
Journal:  Blood       Date:  2016-07-27       Impact factor: 22.113

6.  Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.

Authors:  Yan Chen; Bei Chen; Ti Yang; Weiming Xiao; Li Qian; Yanbing Ding; Mingchun Ji; Xiaoqun Ge; Weijuan Gong
Journal:  Cell Mol Immunol       Date:  2015-09-14       Impact factor: 11.530

Review 7.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

8.  Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.

Authors:  A N Hasan; A Selvakumar; E Shabrova; X-R Liu; F Afridi; G Heller; I Riviere; M Sadelain; B Dupont; R J O'Reilly
Journal:  Clin Exp Immunol       Date:  2016-08-31       Impact factor: 4.330

Review 9.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

10.  Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO.

Authors:  Chantiya Chanswangphuwana; David S J Allan; Mala Chakraborty; Robert N Reger; Richard W Childs
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.